Antengene Corporation Closes US$97M in Partial Series C Financing

Funding will be used to enhance R&D capacity and strengthen existing infrastructure

Antengene Corporation, an innovative hematology and oncology-focused biopharmaceutical company, announced on July 20 that it had successfully closed US$97 million in Series C financing, to support ongoing drug development and preparations for potential commercialization. 

The financing was led by Fidelity Management & Research Company LLC with additional support from new investors including GL Ventures, GIC, and a large, reputable long-term investor. Existing investors including Qiming Venture Partners and Boyu Capital also participated in the funding. 

China- and U.S.-based Antengene’s activities include integrated drug discovery, clinical development, manufacturing and commercialization. Over the past 3 years, Antengene has developed 12 clinical and pre-clinical stage programs and obtained 7 IND approvals with 10 ongoing cross-regional clinical trials in the Asia Pacific region. 

With a vision of “Treating Patients Beyond Borders,” the company aspires to meet the unmet medical needs of patients in the Asia Pacific regions and around the world through research & development into top quality anti-cancer drugs and treatments. Antengene has partnerships with a number of bg players in the industry, including Celgene, Karyopharm Therapeutics and AstraZeneca. 

Proceeds from the Series C financing will mainly be used to fund the continuing clinical development of Antengene’s hematology and oncology therapies, enhancing in-house research and development capabilities and strengthening the commercial infrastructures in APAC markets. 

To date, Antengene has made significant progress with its broad pipeline of six clinical-stage programs and six pre-clinical stage oncology assets. The company has developed compounds which are now used in the treatment of a number of diseases, including myeloma, carcinoma, and other types of malignancies and cancers. 

In 2019, funding for healthtech innovators exceeded US$7.4 billion, and research shows that investors continue to invest significantly in this field. The health tech industry is particularly significant in China, where authorities are attempting to meet the healthcare demands of the population with their supply of medical resources. The global pandemic has further necessitated research and development in the field of health tech. 

Dr. Jay Mei, Founder, Chairman and CEO of Antengene says, “We appreciate the recognition and trust from these prestigious investment institutions. This round of financing has drawn support from among the world’s largest asset managers, top-tier healthcare investors widely recognized in the capital markets, and strong continuous support from our existing investors. This is an important milestone to reinforce Antengene’s capabilities to bring cutting-edge therapies to help patients with life-threatening diseases in the Asia Pacific regions and around the world.”

Header image courtesy of Louis Reed on Unsplash.

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email

RELATED POSTS

How Can Your Company Become More Energy-Efficient

How Can Your Company Become More Energy-Efficient?

Countries and companies are consuming too much energy today. The abrupt power cuts in China are a testimony to that. The country was forced to cut power across factories and towns to meet their energy goals. Energy efficiency—using less energy to do more—does not have to be this challenging and cumbersome, not for large corporations or startups.

Cyberport Venture Capital Forum

How Will Humans and Technology Interact in the Next Decades?

While the world has witnessed a rapid digitalization of our everyday life in the course of the pandemic, attention has been brought to the debate that has long been around–how should humans and technology interact? And how do we prepare for new developments? In response to this, Dr. David Siegel, Co-Chairman and Co-Founder of financial sciences company Two Sigma.

Top 5 NFT Scam

Top 5 NFT Scam

From art pieces like EVERYDAYS: THE FIRST 5000 DAYS by Mike Winkelmann to cryptopunks and memes like Side-eyeing Chloe, the popularity of Non-Fungible Tokens (NFT) has been on the uptick. They have also been blowing up in value in 2021. NFT sale volumes have surged eightfold, reaching US$10.7 billion in the third quarter of 2021.

What Brands Must Know About China’s Evolving Millennial Buyers

What Brands Must Know About China’s Evolving Millennial Buyers

Earlier this year, climate activist Greta Thunberg called out fast fashion consumers during an interview with a fashion magazine. She said, “If you are buying fast fashion, then you are contributing to that industry and encouraging them to expand and encouraging them to continue their harmful process.”

What Is Femtech and Are Femtech Companies on the Rise

What Is Femtech and Are Femtech Companies on the Rise?

Women’s needs have been largely neglected for years. They get fewer job opportunities, excessive household work, subpar pay and little healthcare attention. Well, no more. The rise of FemTech startups (largely women-run) is changing the healthcare landscape for women. As per a report by CBInsights, FemTech will be worth US$50 billion by 2025. So, what is FemTech, and how can you get started?